Tarsus Pharmaceuticals (TARS) Operating Income (2019 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Operating Income of -$6.1 million for Q1 2026, up 76.7% year-over-year from -$3.5 million in Q1 2025, and up 23.24% quarter-over-quarter from -$8.0 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) Operating Income (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Operating Income history runs 8 years deep, the most recent figure standing at -$6.1 million for Q1 2026.
- In Q1 2026, Operating Income rose 76.7% year-over-year to -$6.1 million; the TTM figure through Mar 2026 stood at -$50.8 million (up 53.45% YoY), while the FY2025 annual figure was -$71.0 million, up 41.14% from the prior year.
- Operating Income for Q1 2026 stood at -$6.1 million, up from -$8.0 million in the prior quarter.
- The five-year high for Operating Income was -$5.2 million in Q2 2022, with the low at -$44.4 million in Q4 2023.
- The 5-year median for Operating Income is -$24.4 million (2024), against an average of -$23.7 million.
- The sharpest annual moves came in 2023 and 2026: Operating Income slumped 528.27% in 2023, then soared 76.7% in 2026.
- Tarsus Pharmaceuticals' Operating Income stood at -$15.1 million in 2022, then sank by 195.13% to -$44.4 million in 2023, then jumped by 45.06% to -$24.4 million in 2024, then surged by 67.34% to -$8.0 million in 2025, then rose by 23.24% to -$6.1 million in 2026.
- Business Quant data shows TARS's Operating Income at -$6.1 million in Q1 2026, -$8.0 million in Q4 2025, and -$14.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn | -19.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.91 Mn |
| Mar 31, 2026 | -6.12 Mn |
| Dec 31, 2025 | -7.98 Mn |
| Sep 30, 2025 | -14.53 Mn |
| Jun 30, 2025 | -22.18 Mn |
| Mar 31, 2025 | -26.28 Mn |
| Dec 31, 2024 | -24.42 Mn |
| Sep 30, 2024 | -25.16 Mn |
| Jun 30, 2024 | -33.30 Mn |
| Mar 31, 2024 | -37.68 Mn |
| Dec 31, 2023 | -44.45 Mn |
| Sep 30, 2023 | -40.94 Mn |
| Jun 30, 2023 | -32.82 Mn |
| Mar 31, 2023 | -24.95 Mn |
| Dec 31, 2022 | -15.06 Mn |
| Sep 30, 2022 | -22.91 Mn |
| Jun 30, 2022 | -5.22 Mn |
| Mar 31, 2022 | -19.52 Mn |
| Dec 31, 2021 | -14.45 Mn |
| Sep 30, 2021 | -15.71 Mn |